nodes	percent_of_prediction	percent_of_DWPC	metapath
Metronidazole—CYP2C9—Capecitabine—esophageal cancer	0.177	0.665	CbGbCtD
Metronidazole—CYP2C9—Cisplatin—esophageal cancer	0.0894	0.335	CbGbCtD
Metronidazole—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00252	0.0144	CbGpPWpGaD
Metronidazole—Urine output increased—Capecitabine—esophageal cancer	0.00247	0.00442	CcSEcCtD
Metronidazole—Neoplasm—Capecitabine—esophageal cancer	0.00247	0.00442	CcSEcCtD
Metronidazole—Breast disorder—Cisplatin—esophageal cancer	0.00243	0.00435	CcSEcCtD
Metronidazole—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00242	0.0138	CbGpPWpGaD
Metronidazole—Cramp muscle—Cisplatin—esophageal cancer	0.00242	0.00434	CcSEcCtD
Metronidazole—Nasopharyngitis—Cisplatin—esophageal cancer	0.0024	0.00431	CcSEcCtD
Metronidazole—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00231	0.0132	CbGpPWpGaD
Metronidazole—CYP2C9—Xenobiotics—CYP2A6—esophageal cancer	0.0023	0.0131	CbGpPWpGaD
Metronidazole—Thrombophlebitis—Capecitabine—esophageal cancer	0.00229	0.0041	CcSEcCtD
Metronidazole—Pancreatitis—Cisplatin—esophageal cancer	0.00228	0.00408	CcSEcCtD
Metronidazole—Polyuria—Capecitabine—esophageal cancer	0.00226	0.00404	CcSEcCtD
Metronidazole—Photosensitivity—Capecitabine—esophageal cancer	0.00226	0.00404	CcSEcCtD
Metronidazole—Abdominal discomfort—Cisplatin—esophageal cancer	0.00223	0.00399	CcSEcCtD
Metronidazole—CYP2C9—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00221	0.0126	CbGpPWpGaD
Metronidazole—Pancytopenia—Cisplatin—esophageal cancer	0.00221	0.00395	CcSEcCtD
Metronidazole—Glossitis—Methotrexate—esophageal cancer	0.0022	0.00395	CcSEcCtD
Metronidazole—Hepatic failure—Capecitabine—esophageal cancer	0.0022	0.00395	CcSEcCtD
Metronidazole—CYP2C8—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00219	0.0125	CbGpPWpGaD
Metronidazole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00216	0.0123	CbGpPWpGaD
Metronidazole—Dysarthria—Methotrexate—esophageal cancer	0.00215	0.00385	CcSEcCtD
Metronidazole—Libido decreased—Capecitabine—esophageal cancer	0.00214	0.00383	CcSEcCtD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00211	0.0121	CbGpPWpGaD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00211	0.0121	CbGpPWpGaD
Metronidazole—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00209	0.012	CbGpPWpGaD
Metronidazole—Dermatitis bullous—Capecitabine—esophageal cancer	0.00207	0.00371	CcSEcCtD
Metronidazole—Vaginal inflammation—Methotrexate—esophageal cancer	0.00203	0.00364	CcSEcCtD
Metronidazole—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00203	0.00364	CcSEcCtD
Metronidazole—Stomatitis—Cisplatin—esophageal cancer	0.00202	0.00362	CcSEcCtD
Metronidazole—Conjunctivitis—Cisplatin—esophageal cancer	0.00201	0.00361	CcSEcCtD
Metronidazole—Cystitis noninfective—Methotrexate—esophageal cancer	0.00198	0.00356	CcSEcCtD
Metronidazole—Diplopia—Capecitabine—esophageal cancer	0.00198	0.00355	CcSEcCtD
Metronidazole—Osteoarthritis—Capecitabine—esophageal cancer	0.00198	0.00355	CcSEcCtD
Metronidazole—CYP2C9—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00197	0.0113	CbGpPWpGaD
Metronidazole—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00197	0.00352	CcSEcCtD
Metronidazole—Cystitis—Methotrexate—esophageal cancer	0.00196	0.00351	CcSEcCtD
Metronidazole—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00196	0.00351	CcSEcCtD
Metronidazole—Skin exfoliation—Methotrexate—esophageal cancer	0.00194	0.00347	CcSEcCtD
Metronidazole—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00193	0.011	CbGpPWpGaD
Metronidazole—Vaginal infection—Methotrexate—esophageal cancer	0.00192	0.00344	CcSEcCtD
Metronidazole—Aplastic anaemia—Methotrexate—esophageal cancer	0.00191	0.00342	CcSEcCtD
Metronidazole—Irritability—Capecitabine—esophageal cancer	0.00189	0.00339	CcSEcCtD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00188	0.0107	CbGpPWpGaD
Metronidazole—Ataxia—Capecitabine—esophageal cancer	0.00186	0.00334	CcSEcCtD
Metronidazole—CYP2C8—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00186	0.0106	CbGpPWpGaD
Metronidazole—Urine output increased—Methotrexate—esophageal cancer	0.00184	0.00329	CcSEcCtD
Metronidazole—Bladder pain—Methotrexate—esophageal cancer	0.00184	0.00329	CcSEcCtD
Metronidazole—Neoplasm—Methotrexate—esophageal cancer	0.00184	0.00329	CcSEcCtD
Metronidazole—Liver function test abnormal—Capecitabine—esophageal cancer	0.00183	0.00328	CcSEcCtD
Metronidazole—Connective tissue disorder—Cisplatin—esophageal cancer	0.00183	0.00327	CcSEcCtD
Metronidazole—Gynaecomastia—Methotrexate—esophageal cancer	0.00182	0.00326	CcSEcCtD
Metronidazole—Dry skin—Capecitabine—esophageal cancer	0.00182	0.00325	CcSEcCtD
Metronidazole—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00181	0.0104	CbGpPWpGaD
Metronidazole—Abdominal pain upper—Capecitabine—esophageal cancer	0.00181	0.00324	CcSEcCtD
Metronidazole—Visual impairment—Cisplatin—esophageal cancer	0.00179	0.00321	CcSEcCtD
Metronidazole—Breast disorder—Capecitabine—esophageal cancer	0.00179	0.00321	CcSEcCtD
Metronidazole—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00178	0.0032	CcSEcCtD
Metronidazole—CYP2C9—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00178	0.0102	CbGpPWpGaD
Metronidazole—Nasopharyngitis—Capecitabine—esophageal cancer	0.00177	0.00317	CcSEcCtD
Metronidazole—Eye disorder—Cisplatin—esophageal cancer	0.00174	0.00311	CcSEcCtD
Metronidazole—Tinnitus—Cisplatin—esophageal cancer	0.00173	0.00311	CcSEcCtD
Metronidazole—Flushing—Cisplatin—esophageal cancer	0.00173	0.00309	CcSEcCtD
Metronidazole—Cardiac disorder—Cisplatin—esophageal cancer	0.00173	0.00309	CcSEcCtD
Metronidazole—Abdominal distension—Capecitabine—esophageal cancer	0.00172	0.00309	CcSEcCtD
Metronidazole—Asthma—Capecitabine—esophageal cancer	0.00171	0.00307	CcSEcCtD
Metronidazole—Influenza—Capecitabine—esophageal cancer	0.00171	0.00307	CcSEcCtD
Metronidazole—Thrombophlebitis—Methotrexate—esophageal cancer	0.0017	0.00305	CcSEcCtD
Metronidazole—Polyuria—Methotrexate—esophageal cancer	0.00168	0.00301	CcSEcCtD
Metronidazole—Photosensitivity—Methotrexate—esophageal cancer	0.00168	0.00301	CcSEcCtD
Metronidazole—Immune system disorder—Cisplatin—esophageal cancer	0.00168	0.00301	CcSEcCtD
Metronidazole—Mediastinal disorder—Cisplatin—esophageal cancer	0.00168	0.003	CcSEcCtD
Metronidazole—Bronchitis—Capecitabine—esophageal cancer	0.00165	0.00295	CcSEcCtD
Metronidazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00165	0.00941	CbGpPWpGaD
Metronidazole—Abdominal discomfort—Capecitabine—esophageal cancer	0.00164	0.00294	CcSEcCtD
Metronidazole—Hepatic failure—Methotrexate—esophageal cancer	0.00164	0.00294	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00164	0.00935	CbGpPWpGaD
Metronidazole—Pancytopenia—Capecitabine—esophageal cancer	0.00163	0.00291	CcSEcCtD
Metronidazole—CYP2C8—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00162	0.00928	CbGpPWpGaD
Metronidazole—Erythema—Cisplatin—esophageal cancer	0.00162	0.0029	CcSEcCtD
Metronidazole—Neutropenia—Capecitabine—esophageal cancer	0.0016	0.00287	CcSEcCtD
Metronidazole—Dysuria—Capecitabine—esophageal cancer	0.0016	0.00287	CcSEcCtD
Metronidazole—Flatulence—Cisplatin—esophageal cancer	0.00159	0.00286	CcSEcCtD
Metronidazole—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00159	0.00285	CcSEcCtD
Metronidazole—CYP2C9—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00158	0.00902	CbGpPWpGaD
Metronidazole—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00156	0.0028	CcSEcCtD
Metronidazole—Muscle spasms—Cisplatin—esophageal cancer	0.00156	0.00279	CcSEcCtD
Metronidazole—Infestation NOS—Capecitabine—esophageal cancer	0.00153	0.00274	CcSEcCtD
Metronidazole—Infestation—Capecitabine—esophageal cancer	0.00153	0.00274	CcSEcCtD
Metronidazole—Vision blurred—Cisplatin—esophageal cancer	0.00153	0.00273	CcSEcCtD
Metronidazole—Depression—Capecitabine—esophageal cancer	0.00152	0.00273	CcSEcCtD
Metronidazole—Tremor—Cisplatin—esophageal cancer	0.00152	0.00272	CcSEcCtD
Metronidazole—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00152	0.00866	CbGpPWpGaD
Metronidazole—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00151	0.00271	CcSEcCtD
Metronidazole—CYP2C9—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00151	0.00863	CbGpPWpGaD
Metronidazole—Neuropathy peripheral—Capecitabine—esophageal cancer	0.0015	0.00268	CcSEcCtD
Metronidazole—Stomatitis—Capecitabine—esophageal cancer	0.00149	0.00267	CcSEcCtD
Metronidazole—Jaundice—Capecitabine—esophageal cancer	0.00149	0.00267	CcSEcCtD
Metronidazole—Urinary tract infection—Capecitabine—esophageal cancer	0.00148	0.00266	CcSEcCtD
Metronidazole—Conjunctivitis—Capecitabine—esophageal cancer	0.00148	0.00266	CcSEcCtD
Metronidazole—Osteoarthritis—Methotrexate—esophageal cancer	0.00147	0.00264	CcSEcCtD
Metronidazole—Malaise—Cisplatin—esophageal cancer	0.00146	0.00261	CcSEcCtD
Metronidazole—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00146	0.00833	CbGpPWpGaD
Metronidazole—Leukopenia—Cisplatin—esophageal cancer	0.00145	0.0026	CcSEcCtD
Metronidazole—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00144	0.00259	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00144	0.0082	CbGpPWpGaD
Metronidazole—Agranulocytosis—Capecitabine—esophageal cancer	0.00142	0.00255	CcSEcCtD
Metronidazole—Irritability—Methotrexate—esophageal cancer	0.00141	0.00252	CcSEcCtD
Metronidazole—Convulsion—Cisplatin—esophageal cancer	0.0014	0.00251	CcSEcCtD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00139	0.00795	CbGpPWpGaD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00139	0.00795	CbGpPWpGaD
Metronidazole—Ataxia—Methotrexate—esophageal cancer	0.00139	0.00248	CcSEcCtD
Metronidazole—Rhinitis—Capecitabine—esophageal cancer	0.00137	0.00246	CcSEcCtD
Metronidazole—Hepatitis—Capecitabine—esophageal cancer	0.00137	0.00246	CcSEcCtD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00137	0.00245	CcSEcCtD
Metronidazole—Hypoaesthesia—Capecitabine—esophageal cancer	0.00136	0.00244	CcSEcCtD
Metronidazole—Liver function test abnormal—Methotrexate—esophageal cancer	0.00136	0.00244	CcSEcCtD
Metronidazole—Pharyngitis—Capecitabine—esophageal cancer	0.00136	0.00244	CcSEcCtD
Metronidazole—Connective tissue disorder—Capecitabine—esophageal cancer	0.00135	0.00241	CcSEcCtD
Metronidazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00134	0.00765	CbGpPWpGaD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00133	0.00762	CbGpPWpGaD
Metronidazole—Breast disorder—Methotrexate—esophageal cancer	0.00133	0.00239	CcSEcCtD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00133	0.00761	CbGpPWpGaD
Metronidazole—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00133	0.0076	CbGpPWpGaD
Metronidazole—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00133	0.00238	CcSEcCtD
Metronidazole—CYP2C9—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00132	0.00755	CbGpPWpGaD
Metronidazole—Anaphylactic shock—Cisplatin—esophageal cancer	0.00132	0.00237	CcSEcCtD
Metronidazole—Oedema—Cisplatin—esophageal cancer	0.00132	0.00237	CcSEcCtD
Metronidazole—Visual impairment—Capecitabine—esophageal cancer	0.00132	0.00237	CcSEcCtD
Metronidazole—Infection—Cisplatin—esophageal cancer	0.00131	0.00235	CcSEcCtD
Metronidazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.0013	0.00744	CbGpPWpGaD
Metronidazole—Erythema multiforme—Capecitabine—esophageal cancer	0.0013	0.00232	CcSEcCtD
Metronidazole—Nervous system disorder—Cisplatin—esophageal cancer	0.0013	0.00232	CcSEcCtD
Metronidazole—Thrombocytopenia—Cisplatin—esophageal cancer	0.00129	0.00232	CcSEcCtD
Metronidazole—CYP2C8—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00129	0.00735	CbGpPWpGaD
Metronidazole—Skin disorder—Cisplatin—esophageal cancer	0.00128	0.0023	CcSEcCtD
Metronidazole—Eye disorder—Capecitabine—esophageal cancer	0.00128	0.00229	CcSEcCtD
Metronidazole—Tinnitus—Capecitabine—esophageal cancer	0.00128	0.00229	CcSEcCtD
Metronidazole—Hyperhidrosis—Cisplatin—esophageal cancer	0.00128	0.00229	CcSEcCtD
Metronidazole—Asthma—Methotrexate—esophageal cancer	0.00127	0.00228	CcSEcCtD
Metronidazole—Flushing—Capecitabine—esophageal cancer	0.00127	0.00228	CcSEcCtD
Metronidazole—Cardiac disorder—Capecitabine—esophageal cancer	0.00127	0.00228	CcSEcCtD
Metronidazole—Eosinophilia—Methotrexate—esophageal cancer	0.00126	0.00226	CcSEcCtD
Metronidazole—Anorexia—Cisplatin—esophageal cancer	0.00126	0.00226	CcSEcCtD
Metronidazole—Pancreatitis—Methotrexate—esophageal cancer	0.00125	0.00224	CcSEcCtD
Metronidazole—Angiopathy—Capecitabine—esophageal cancer	0.00124	0.00223	CcSEcCtD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00124	0.00709	CbGpPWpGaD
Metronidazole—Immune system disorder—Capecitabine—esophageal cancer	0.00124	0.00222	CcSEcCtD
Metronidazole—Mediastinal disorder—Capecitabine—esophageal cancer	0.00123	0.00221	CcSEcCtD
Metronidazole—Abdominal discomfort—Methotrexate—esophageal cancer	0.00122	0.00219	CcSEcCtD
Metronidazole—Pancytopenia—Methotrexate—esophageal cancer	0.00121	0.00217	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.0012	0.00216	CcSEcCtD
Metronidazole—Mental disorder—Capecitabine—esophageal cancer	0.0012	0.00215	CcSEcCtD
Metronidazole—Erythema—Capecitabine—esophageal cancer	0.00119	0.00214	CcSEcCtD
Metronidazole—Neutropenia—Methotrexate—esophageal cancer	0.00119	0.00214	CcSEcCtD
Metronidazole—Dysuria—Methotrexate—esophageal cancer	0.00119	0.00214	CcSEcCtD
Metronidazole—Paraesthesia—Cisplatin—esophageal cancer	0.00119	0.00212	CcSEcCtD
Metronidazole—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00118	0.00212	CcSEcCtD
Metronidazole—Flatulence—Capecitabine—esophageal cancer	0.00118	0.00211	CcSEcCtD
Metronidazole—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00118	0.00672	CbGpPWpGaD
Metronidazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00117	0.0067	CbGpPWpGaD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00117	0.00668	CbGpPWpGaD
Metronidazole—Dysgeusia—Capecitabine—esophageal cancer	0.00117	0.00209	CcSEcCtD
Metronidazole—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00116	0.00208	CcSEcCtD
Metronidazole—CYP2C8—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00116	0.00661	CbGpPWpGaD
Metronidazole—Back pain—Capecitabine—esophageal cancer	0.00115	0.00207	CcSEcCtD
Metronidazole—Decreased appetite—Cisplatin—esophageal cancer	0.00115	0.00206	CcSEcCtD
Metronidazole—Muscle spasms—Capecitabine—esophageal cancer	0.00115	0.00205	CcSEcCtD
Metronidazole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00115	0.00655	CbGpPWpGaD
Metronidazole—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00114	0.00204	CcSEcCtD
Metronidazole—Infestation—Methotrexate—esophageal cancer	0.00114	0.00204	CcSEcCtD
Metronidazole—Infestation NOS—Methotrexate—esophageal cancer	0.00114	0.00204	CcSEcCtD
Metronidazole—Drowsiness—Methotrexate—esophageal cancer	0.00114	0.00204	CcSEcCtD
Metronidazole—Depression—Methotrexate—esophageal cancer	0.00113	0.00203	CcSEcCtD
Metronidazole—Pain—Cisplatin—esophageal cancer	0.00113	0.00202	CcSEcCtD
Metronidazole—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00113	0.00202	CcSEcCtD
Metronidazole—Vision blurred—Capecitabine—esophageal cancer	0.00112	0.00201	CcSEcCtD
Metronidazole—Tremor—Capecitabine—esophageal cancer	0.00112	0.002	CcSEcCtD
Metronidazole—Stomatitis—Methotrexate—esophageal cancer	0.00111	0.00198	CcSEcCtD
Metronidazole—Conjunctivitis—Methotrexate—esophageal cancer	0.0011	0.00198	CcSEcCtD
Metronidazole—CYP2C8—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00109	0.00625	CbGpPWpGaD
Metronidazole—Sweating—Methotrexate—esophageal cancer	0.00109	0.00195	CcSEcCtD
Metronidazole—Feeling abnormal—Cisplatin—esophageal cancer	0.00109	0.00195	CcSEcCtD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00109	0.00621	CbGpPWpGaD
Metronidazole—Malaise—Capecitabine—esophageal cancer	0.00108	0.00193	CcSEcCtD
Metronidazole—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00107	0.00193	CcSEcCtD
Metronidazole—Vertigo—Capecitabine—esophageal cancer	0.00107	0.00192	CcSEcCtD
Metronidazole—Syncope—Capecitabine—esophageal cancer	0.00107	0.00192	CcSEcCtD
Metronidazole—Leukopenia—Capecitabine—esophageal cancer	0.00107	0.00191	CcSEcCtD
Metronidazole—Agranulocytosis—Methotrexate—esophageal cancer	0.00106	0.0019	CcSEcCtD
Metronidazole—Palpitations—Capecitabine—esophageal cancer	0.00105	0.00189	CcSEcCtD
Metronidazole—Loss of consciousness—Capecitabine—esophageal cancer	0.00105	0.00188	CcSEcCtD
Metronidazole—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00105	0.00599	CbGpPWpGaD
Metronidazole—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00105	0.00598	CbGpPWpGaD
Metronidazole—Body temperature increased—Cisplatin—esophageal cancer	0.00104	0.00187	CcSEcCtD
Metronidazole—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00104	0.00595	CbGpPWpGaD
Metronidazole—Hypertension—Capecitabine—esophageal cancer	0.00103	0.00185	CcSEcCtD
Metronidazole—Hepatitis—Methotrexate—esophageal cancer	0.00102	0.00183	CcSEcCtD
Metronidazole—Arthralgia—Capecitabine—esophageal cancer	0.00102	0.00182	CcSEcCtD
Metronidazole—Chest pain—Capecitabine—esophageal cancer	0.00102	0.00182	CcSEcCtD
Metronidazole—Pharyngitis—Methotrexate—esophageal cancer	0.00101	0.00181	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00101	0.00578	CbGpPWpGaD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00101	0.00181	CcSEcCtD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000998	0.0057	CbGpPWpGaD
Metronidazole—Dry mouth—Capecitabine—esophageal cancer	0.000993	0.00178	CcSEcCtD
Metronidazole—Visual impairment—Methotrexate—esophageal cancer	0.000983	0.00176	CcSEcCtD
Metronidazole—Confusional state—Capecitabine—esophageal cancer	0.000982	0.00176	CcSEcCtD
Metronidazole—Oedema—Capecitabine—esophageal cancer	0.000974	0.00174	CcSEcCtD
Metronidazole—Hypersensitivity—Cisplatin—esophageal cancer	0.000973	0.00174	CcSEcCtD
Metronidazole—Infection—Capecitabine—esophageal cancer	0.000967	0.00173	CcSEcCtD
Metronidazole—Erythema multiforme—Methotrexate—esophageal cancer	0.000964	0.00173	CcSEcCtD
Metronidazole—Shock—Capecitabine—esophageal cancer	0.000958	0.00172	CcSEcCtD
Metronidazole—Nervous system disorder—Capecitabine—esophageal cancer	0.000955	0.00171	CcSEcCtD
Metronidazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000955	0.00545	CbGpPWpGaD
Metronidazole—Eye disorder—Methotrexate—esophageal cancer	0.000953	0.00171	CcSEcCtD
Metronidazole—Thrombocytopenia—Capecitabine—esophageal cancer	0.000953	0.00171	CcSEcCtD
Metronidazole—Tinnitus—Methotrexate—esophageal cancer	0.000951	0.0017	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000951	0.00543	CbGpPWpGaD
Metronidazole—Asthenia—Cisplatin—esophageal cancer	0.000948	0.0017	CcSEcCtD
Metronidazole—Cardiac disorder—Methotrexate—esophageal cancer	0.000947	0.0017	CcSEcCtD
Metronidazole—Skin disorder—Capecitabine—esophageal cancer	0.000946	0.00169	CcSEcCtD
Metronidazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000945	0.0054	CbGpPWpGaD
Metronidazole—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000942	0.00538	CbGpPWpGaD
Metronidazole—Hyperhidrosis—Capecitabine—esophageal cancer	0.000941	0.00169	CcSEcCtD
Metronidazole—CYP2C8—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000933	0.00533	CbGpPWpGaD
Metronidazole—Anorexia—Capecitabine—esophageal cancer	0.000928	0.00166	CcSEcCtD
Metronidazole—Angiopathy—Methotrexate—esophageal cancer	0.000925	0.00166	CcSEcCtD
Metronidazole—Immune system disorder—Methotrexate—esophageal cancer	0.000921	0.00165	CcSEcCtD
Metronidazole—Mediastinal disorder—Methotrexate—esophageal cancer	0.000919	0.00165	CcSEcCtD
Metronidazole—Diarrhoea—Cisplatin—esophageal cancer	0.000904	0.00162	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000901	0.00515	CbGpPWpGaD
Metronidazole—Mental disorder—Methotrexate—esophageal cancer	0.000894	0.0016	CcSEcCtD
Metronidazole—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00089	0.00509	CbGpPWpGaD
Metronidazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000889	0.00508	CbGpPWpGaD
Metronidazole—Erythema—Methotrexate—esophageal cancer	0.000888	0.00159	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000887	0.00159	CcSEcCtD
Metronidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000883	0.00505	CbGpPWpGaD
Metronidazole—Insomnia—Capecitabine—esophageal cancer	0.000881	0.00158	CcSEcCtD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000879	0.00502	CbGpPWpGaD
Metronidazole—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000877	0.00501	CbGpPWpGaD
Metronidazole—Paraesthesia—Capecitabine—esophageal cancer	0.000874	0.00157	CcSEcCtD
Metronidazole—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000872	0.00498	CbGpPWpGaD
Metronidazole—Dysgeusia—Methotrexate—esophageal cancer	0.00087	0.00156	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—ADH7—esophageal cancer	0.00087	0.00497	CbGpPWpGaD
Metronidazole—Back pain—Methotrexate—esophageal cancer	0.000859	0.00154	CcSEcCtD
Metronidazole—Dyspepsia—Capecitabine—esophageal cancer	0.000857	0.00154	CcSEcCtD
Metronidazole—Decreased appetite—Capecitabine—esophageal cancer	0.000846	0.00152	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00084	0.00151	CcSEcCtD
Metronidazole—Vomiting—Cisplatin—esophageal cancer	0.00084	0.0015	CcSEcCtD
Metronidazole—Fatigue—Capecitabine—esophageal cancer	0.000839	0.0015	CcSEcCtD
Metronidazole—Vision blurred—Methotrexate—esophageal cancer	0.000837	0.0015	CcSEcCtD
Metronidazole—Rash—Cisplatin—esophageal cancer	0.000833	0.00149	CcSEcCtD
Metronidazole—Constipation—Capecitabine—esophageal cancer	0.000833	0.00149	CcSEcCtD
Metronidazole—Pain—Capecitabine—esophageal cancer	0.000833	0.00149	CcSEcCtD
Metronidazole—Dermatitis—Cisplatin—esophageal cancer	0.000832	0.00149	CcSEcCtD
Metronidazole—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000828	0.00473	CbGpPWpGaD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000823	0.0047	CbGpPWpGaD
Metronidazole—Feeling abnormal—Capecitabine—esophageal cancer	0.000802	0.00144	CcSEcCtD
Metronidazole—Malaise—Methotrexate—esophageal cancer	0.000801	0.00143	CcSEcCtD
Metronidazole—Vertigo—Methotrexate—esophageal cancer	0.000798	0.00143	CcSEcCtD
Metronidazole—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000796	0.00143	CcSEcCtD
Metronidazole—Leukopenia—Methotrexate—esophageal cancer	0.000795	0.00142	CcSEcCtD
Metronidazole—Nausea—Cisplatin—esophageal cancer	0.000784	0.00141	CcSEcCtD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000774	0.00442	CbGpPWpGaD
Metronidazole—Urticaria—Capecitabine—esophageal cancer	0.000773	0.00139	CcSEcCtD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00077	0.0044	CbGpPWpGaD
Metronidazole—Abdominal pain—Capecitabine—esophageal cancer	0.00077	0.00138	CcSEcCtD
Metronidazole—Body temperature increased—Capecitabine—esophageal cancer	0.00077	0.00138	CcSEcCtD
Metronidazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000769	0.0044	CbGpPWpGaD
Metronidazole—Convulsion—Methotrexate—esophageal cancer	0.000769	0.00138	CcSEcCtD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000766	0.00438	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—ADH1B—esophageal cancer	0.000762	0.00436	CbGpPWpGaD
Metronidazole—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000759	0.00434	CbGpPWpGaD
Metronidazole—Arthralgia—Methotrexate—esophageal cancer	0.000756	0.00135	CcSEcCtD
Metronidazole—Chest pain—Methotrexate—esophageal cancer	0.000756	0.00135	CcSEcCtD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000751	0.00135	CcSEcCtD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000734	0.00419	CbGpPWpGaD
Metronidazole—Confusional state—Methotrexate—esophageal cancer	0.000731	0.00131	CcSEcCtD
Metronidazole—Anaphylactic shock—Methotrexate—esophageal cancer	0.000725	0.0013	CcSEcCtD
Metronidazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000723	0.00413	CbGpPWpGaD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000721	0.00412	CbGpPWpGaD
Metronidazole—Infection—Methotrexate—esophageal cancer	0.00072	0.00129	CcSEcCtD
Metronidazole—Hypersensitivity—Capecitabine—esophageal cancer	0.000717	0.00129	CcSEcCtD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000716	0.00409	CbGpPWpGaD
Metronidazole—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000714	0.00408	CbGpPWpGaD
Metronidazole—Nervous system disorder—Methotrexate—esophageal cancer	0.000711	0.00127	CcSEcCtD
Metronidazole—Thrombocytopenia—Methotrexate—esophageal cancer	0.00071	0.00127	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—CYP26A1—esophageal cancer	0.000709	0.00405	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.000708	0.00404	CbGpPWpGaD
Metronidazole—Skin disorder—Methotrexate—esophageal cancer	0.000704	0.00126	CcSEcCtD
Metronidazole—Hyperhidrosis—Methotrexate—esophageal cancer	0.000701	0.00126	CcSEcCtD
Metronidazole—CYP2C8—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000699	0.00399	CbGpPWpGaD
Metronidazole—Asthenia—Capecitabine—esophageal cancer	0.000698	0.00125	CcSEcCtD
Metronidazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000691	0.00395	CbGpPWpGaD
Metronidazole—Anorexia—Methotrexate—esophageal cancer	0.000691	0.00124	CcSEcCtD
Metronidazole—Pruritus—Capecitabine—esophageal cancer	0.000689	0.00123	CcSEcCtD
Metronidazole—Diarrhoea—Capecitabine—esophageal cancer	0.000666	0.00119	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00066	0.00118	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTO1—esophageal cancer	0.000659	0.00377	CbGpPWpGaD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000658	0.00376	CbGpPWpGaD
Metronidazole—Insomnia—Methotrexate—esophageal cancer	0.000655	0.00117	CcSEcCtD
Metronidazole—Paraesthesia—Methotrexate—esophageal cancer	0.000651	0.00117	CcSEcCtD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTO1—esophageal cancer	0.00065	0.00371	CbGpPWpGaD
Metronidazole—Somnolence—Methotrexate—esophageal cancer	0.000644	0.00115	CcSEcCtD
Metronidazole—Dizziness—Capecitabine—esophageal cancer	0.000644	0.00115	CcSEcCtD
Metronidazole—Dyspepsia—Methotrexate—esophageal cancer	0.000638	0.00114	CcSEcCtD
Metronidazole—Decreased appetite—Methotrexate—esophageal cancer	0.00063	0.00113	CcSEcCtD
Metronidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00063	0.0036	CbGpPWpGaD
Metronidazole—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000628	0.00359	CbGpPWpGaD
Metronidazole—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000626	0.00112	CcSEcCtD
Metronidazole—Fatigue—Methotrexate—esophageal cancer	0.000625	0.00112	CcSEcCtD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000624	0.00356	CbGpPWpGaD
Metronidazole—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000621	0.00355	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.000621	0.00355	CbGpPWpGaD
Metronidazole—Pain—Methotrexate—esophageal cancer	0.00062	0.00111	CcSEcCtD
Metronidazole—Vomiting—Capecitabine—esophageal cancer	0.000619	0.00111	CcSEcCtD
Metronidazole—Rash—Capecitabine—esophageal cancer	0.000614	0.0011	CcSEcCtD
Metronidazole—Dermatitis—Capecitabine—esophageal cancer	0.000613	0.0011	CcSEcCtD
Metronidazole—Headache—Capecitabine—esophageal cancer	0.00061	0.00109	CcSEcCtD
Metronidazole—Feeling abnormal—Methotrexate—esophageal cancer	0.000597	0.00107	CcSEcCtD
Metronidazole—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000593	0.00106	CcSEcCtD
Metronidazole—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00059	0.00337	CbGpPWpGaD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000586	0.00335	CbGpPWpGaD
Metronidazole—Nausea—Capecitabine—esophageal cancer	0.000578	0.00104	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000577	0.0033	CbGpPWpGaD
Metronidazole—Urticaria—Methotrexate—esophageal cancer	0.000576	0.00103	CcSEcCtD
Metronidazole—Body temperature increased—Methotrexate—esophageal cancer	0.000573	0.00103	CcSEcCtD
Metronidazole—Abdominal pain—Methotrexate—esophageal cancer	0.000573	0.00103	CcSEcCtD
Metronidazole—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000569	0.00325	CbGpPWpGaD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000543	0.0031	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—ALDH2—esophageal cancer	0.000537	0.00307	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000536	0.00306	CbGpPWpGaD
Metronidazole—Hypersensitivity—Methotrexate—esophageal cancer	0.000534	0.000957	CcSEcCtD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000529	0.00302	CbGpPWpGaD
Metronidazole—Asthenia—Methotrexate—esophageal cancer	0.00052	0.000932	CcSEcCtD
Metronidazole—Pruritus—Methotrexate—esophageal cancer	0.000513	0.000919	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTT1—esophageal cancer	0.000511	0.00292	CbGpPWpGaD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00051	0.00292	CbGpPWpGaD
Metronidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000507	0.0029	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—CYP2A6—esophageal cancer	0.000505	0.00289	CbGpPWpGaD
Metronidazole—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000501	0.00286	CbGpPWpGaD
Metronidazole—Diarrhoea—Methotrexate—esophageal cancer	0.000496	0.000889	CcSEcCtD
Metronidazole—CYP2C8—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000493	0.00282	CbGpPWpGaD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000484	0.00276	CbGpPWpGaD
Metronidazole—Dizziness—Methotrexate—esophageal cancer	0.000479	0.000859	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—PTGS1—esophageal cancer	0.000479	0.00274	CbGpPWpGaD
Metronidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000477	0.00273	CbGpPWpGaD
Metronidazole—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000471	0.00269	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000467	0.00267	CbGpPWpGaD
Metronidazole—Vomiting—Methotrexate—esophageal cancer	0.000461	0.000826	CcSEcCtD
Metronidazole—Rash—Methotrexate—esophageal cancer	0.000457	0.000819	CcSEcCtD
Metronidazole—Dermatitis—Methotrexate—esophageal cancer	0.000457	0.000818	CcSEcCtD
Metronidazole—Headache—Methotrexate—esophageal cancer	0.000454	0.000814	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000437	0.0025	CbGpPWpGaD
Metronidazole—Nausea—Methotrexate—esophageal cancer	0.00043	0.000771	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000416	0.00238	CbGpPWpGaD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000411	0.00235	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000411	0.00235	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000409	0.00234	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—CYP1B1—esophageal cancer	0.000407	0.00233	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000402	0.00229	CbGpPWpGaD
Metronidazole—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000401	0.00229	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000393	0.00224	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.00039	0.00223	CbGpPWpGaD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000387	0.00221	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—CYP19A1—esophageal cancer	0.000383	0.00219	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.00038	0.00217	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000378	0.00216	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000375	0.00214	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000354	0.00202	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000349	0.00199	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000331	0.00189	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000327	0.00187	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00032	0.00183	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000312	0.00178	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000307	0.00176	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000288	0.00165	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000274	0.00157	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000271	0.00155	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000265	0.00152	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000257	0.00147	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000231	0.00132	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000219	0.00125	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000216	0.00123	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000216	0.00123	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—SLC52A3—esophageal cancer	0.000206	0.00118	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—BLVRB—esophageal cancer	0.000206	0.00118	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000205	0.00117	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000203	0.00116	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000188	0.00108	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000184	0.00105	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CA1—esophageal cancer	0.000175	0.000999	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—SLC10A2—esophageal cancer	0.000175	0.000999	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000167	0.000956	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000167	0.000956	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CA2—esophageal cancer	0.00016	0.000914	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000156	0.000893	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.00015	0.000855	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ADH7—esophageal cancer	0.000149	0.00085	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PLCE1—esophageal cancer	0.000149	0.00085	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000147	0.00084	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CA1—esophageal cancer	0.000142	0.000813	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000142	0.000813	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ADH1B—esophageal cancer	0.00013	0.000745	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CA2—esophageal cancer	0.00013	0.000744	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000127	0.000727	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—TYMP—esophageal cancer	0.000125	0.000712	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CYP26A1—esophageal cancer	0.000121	0.000693	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000121	0.000692	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000121	0.000692	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.00012	0.000684	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ALOX15—esophageal cancer	0.000118	0.000675	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTO1—esophageal cancer	0.000113	0.000644	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—TPI1—esophageal cancer	0.000113	0.000644	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.00011	0.000631	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.00011	0.000631	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ALDOB—esophageal cancer	0.000108	0.000617	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000106	0.000606	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GAPDH—esophageal cancer	0.000104	0.000594	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CRABP1—esophageal cancer	0.000103	0.000589	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000101	0.000579	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CYP26A1—esophageal cancer	9.87e-05	0.000564	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GNG7—esophageal cancer	9.8e-05	0.00056	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ALOX15—esophageal cancer	9.61e-05	0.000549	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.39e-05	0.000536	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CA1—esophageal cancer	9.39e-05	0.000536	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ALDH2—esophageal cancer	9.19e-05	0.000525	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTO1—esophageal cancer	9.17e-05	0.000524	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—TPI1—esophageal cancer	9.17e-05	0.000524	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ALDOB—esophageal cancer	8.79e-05	0.000502	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTT1—esophageal cancer	8.74e-05	0.000499	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CYP2A6—esophageal cancer	8.64e-05	0.000494	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.6e-05	0.000492	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CA2—esophageal cancer	8.59e-05	0.000491	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GAPDH—esophageal cancer	8.46e-05	0.000484	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CRABP1—esophageal cancer	8.39e-05	0.000479	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ENO1—esophageal cancer	8.19e-05	0.000468	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PTGS1—esophageal cancer	8.19e-05	0.000468	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PSME1—esophageal cancer	8.07e-05	0.000461	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PSME2—esophageal cancer	8.07e-05	0.000461	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PLCE1—esophageal cancer	7.98e-05	0.000456	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ADH7—esophageal cancer	7.98e-05	0.000456	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GNG7—esophageal cancer	7.98e-05	0.000456	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ALDH2—esophageal cancer	7.48e-05	0.000427	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTT1—esophageal cancer	7.11e-05	0.000406	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.05e-05	0.000403	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CYP2A6—esophageal cancer	7.03e-05	0.000402	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7e-05	0.0004	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ADH1B—esophageal cancer	7e-05	0.0004	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CYP1B1—esophageal cancer	6.96e-05	0.000398	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—TYMP—esophageal cancer	6.69e-05	0.000382	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ENO1—esophageal cancer	6.66e-05	0.000381	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PTGS1—esophageal cancer	6.66e-05	0.000381	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PSME1—esophageal cancer	6.57e-05	0.000375	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PSME2—esophageal cancer	6.57e-05	0.000375	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CYP19A1—esophageal cancer	6.55e-05	0.000374	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.51e-05	0.000372	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.34e-05	0.000362	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—TPI1—esophageal cancer	6.05e-05	0.000346	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.05e-05	0.000346	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—HMOX1—esophageal cancer	5.97e-05	0.000341	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.86e-05	0.000335	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.8e-05	0.000331	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.73e-05	0.000328	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ABCB1—esophageal cancer	5.73e-05	0.000328	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CYP1B1—esophageal cancer	5.67e-05	0.000324	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.58e-05	0.000319	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.53e-05	0.000316	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CYP19A1—esophageal cancer	5.33e-05	0.000304	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GNG7—esophageal cancer	5.26e-05	0.000301	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ALDH2—esophageal cancer	4.93e-05	0.000282	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—HMOX1—esophageal cancer	4.86e-05	0.000278	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.77e-05	0.000273	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.69e-05	0.000268	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ABCB1—esophageal cancer	4.67e-05	0.000267	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.64e-05	0.000265	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.39e-05	0.000251	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ENO1—esophageal cancer	4.39e-05	0.000251	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.33e-05	0.000248	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PSME1—esophageal cancer	4.33e-05	0.000247	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PSME2—esophageal cancer	4.33e-05	0.000247	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CREBBP—esophageal cancer	3.83e-05	0.000219	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.74e-05	0.000214	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.53e-05	0.000202	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.51e-05	0.000201	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—NOS3—esophageal cancer	3.43e-05	0.000196	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.21e-05	0.000183	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PTGS2—esophageal cancer	3.14e-05	0.000179	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.12e-05	0.000178	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.08e-05	0.000176	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—NOS3—esophageal cancer	2.79e-05	0.00016	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—EP300—esophageal cancer	2.61e-05	0.000149	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.55e-05	0.000146	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—EP300—esophageal cancer	2.12e-05	0.000121	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.06e-05	0.000118	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PIK3CA—esophageal cancer	1.93e-05	0.00011	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—NOS3—esophageal cancer	1.84e-05	0.000105	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.68e-05	9.62e-05	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.57e-05	8.98e-05	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—EP300—esophageal cancer	1.4e-05	8e-05	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.04e-05	5.92e-05	CbGpPWpGaD
